I am an entrepreneur with over 10 years of experience in therapeutic discovery and development for rare genetic diseases. As the founder and CEO of Glycomine in San Francisco, I had successfully built the company to secure $45M in venture capital funding.
I am currently the Director of R&D at MiNA Therapeutics, an early-stage company in London, where I’m responsible for research and pre-clinical development of small activating RNAs as new medicines for rare genetic diseases.
Before I found love for working with startups, I held various positions at Pfizer and BioMarin Pharmaceutical. I received a PhD in chemistry and nanomedicine from Northeastern University in Boston.